openPR Logo
Press release

Investigation announced for Investors in shares of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA)

07-25-2019 10:54 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of investors in Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) shares over potential wrongdoing.

An investigation on behalf of investors in Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) shares over potential wrongdoing.

An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Vanda Pharmaceuticals Inc.

Investors who purchased shares of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) and currently hold any of those NASDAQ: VNDA shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Vanda Pharmaceuticals directors breached their fiduciary duties and caused damage to the company and its shareholders.

On February 25, 2019 a lawsuit was filed against Vanda Pharmaceuticals Inc. (NASDAQ: VNDA)
over alleged violations of Federal Securities Laws. The plaintiff claims that between November 4, 2015 and February 11, 2019, thedefendants made false and/or misleading statements and/or failed to disclose that Vanda was engaged in a fraudulent scheme in which it promoted the off-label use of Fanapt and Hetlioz, that Vanda was fraudulently receiving drug reimbursements from the government by abusing Medicare, Medicaid, and Tricare programs, that as a result of the scheme, Vanda faced legal action from the government, that Vanda’s promotional materials for Fanapt and Hetlioz were false and misleading, garnering regulatory scrutiny from the U.S. Food and Drug Administration, and that as a result, defendants’ statements about Vanda’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Those who purchased shares of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Investors in shares of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) here

News-ID: 1811798 • Views: 290

More Releases from Shareholders Foundation

Investigation announced for NYSE: COF Investors over possible Wrongdoing at Capi …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Capital One Financial Corporation. Investors who are current long term investors in Capital One Financial Corporation (NYSE: COF) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NYSE: COF stocks follows a lawsuit filed
Investigation announced for Long-Term Investors in Acadia Healthcare Company Inc …
An investigation was announced for investors in shares of Acadia Healthcare Company Inc (NASDAQ: ACHC) concerning potential breaches of fiduciary duties by certain directors at Acadia Healthcare Company Inc. Investors who purchased shares of Acadia Healthcare Company Inc (NASDAQ: ACHC) and currently hold any of those NASDAQ: ACHC shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm
Investigation for Investors in shares of PlayAGS, Inc. (NYSE: AGS) announced
An investigation was announced concerning potential securities laws violations by PlayAGS, Inc. in connection with certain financial statements. Investors who purchased shares of PlayAGS, Inc. (NYSE: AGS), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of PlayAGS, Inc. (NYSE: AGS) concerning whether a series of statements
Lawsuit filed for Investors in shares of Spirit AeroSystems Holdings, Inc. (NYSE …
An investor, who purchased shares of Spirit AeroSystems Holdings, Inc. (NYSE: SPR), filed a lawsuit over alleged violations of Federal Securities Laws by Spirit AeroSystems Holdings, Inc. Investors who purchased shares of Spirit AeroSystems Holdings, Inc. (NYSE: SPR) have certain options and for certain investors are short and strict deadlines running. Deadline: April 10, 2020. NYSE: SPR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -

All 5 Releases


More Releases for Vanda

Global Sleep Disorder Therapies Market 2019 - Sleep Number, Vanda Pharmaceutical …
Sleep disorders involve problems with the quality, timing and amount of sleep, which cause problems with functioning and distress during the daytime. In 2018, the global Sleep Disorder Therapies market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025. Apex Market Research, recently published a detailed market research study focused on the “Sleep Disorder Therapies
Global Insomnia Market : Leading Players –Pfizer, Merck, Eisai, Meda Consumer …
Insomnia is a sleep disorder where people have trouble sleeping. They may have difficulty falling asleep, or staying asleep as long as desired. Insomnia is typically followed by daytime sleepiness, low energy, irritability, and a depressed mood. Global Insomnia Market report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends
Insomnia Medication 2018 Global Market Key Players – Eisai, Merck, Pfizer, San …
Insomnia Medication Market 2018 Wiseguyreports.Com adds “Insomnia Medication Market –Market Demand, Growth, Opportunities, Analysis of Top Key Players and Forecast to 2025” To Its Research Database. Report Details: This report provides in depth study of “Insomnia Medication Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Insomnia Medication Market report also provides an in-depth survey of key players in the market which is based on the various objectives
Global Schizophrenia Drugs Market 2018: AstraZeneca, Sumitomo, Johnson & Johnson …
The report entitled Global Schizophrenia Drugs Market 2018 delivers the comprehensive and in-depth research analysis of the key regional industry standing of the Schizophrenia Drugs market on a global level. This report especially focuses on the core regions such as North & South America, Europe, Africa, South & Middle East Asia and Australia and also the key countries like (USA, Canada, UK, France, Germany, Russia, India, China, South Korea and
Global Insomnia Market 2017 : Takeda Pharmaceutical Company, Pernix Therapeutics …
Insomnia A market study based on the " Insomnia Market " across the globe, recently added to the repository of Market Research, is titled ‘Global Insomnia Market 2017’. The research report analyses the historical as well as present performance of the worldwide Insomnia industry, and makes predictions on the future status of Insomnia market on the basis of this analysis. Get Free Sample Copy of Report Here : http://www.marketsnresearch.com/request-for-sample.html?repid=4625 Top Manufacturers Analysis Of